Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 7, 2026, 11:08 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 573 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Osteoporosis Clear all
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Study of Romosozumab (AMG 785) Administered to Healthy Participants and Patients With Stage 4 Renal Impairment or Stage 5 Renal Impairment Requiring Hemodialysis

NCT01833754
View directory record Official record
Conditions
Osteoporosis
Interventions
Romosozumab
Drug
Lead sponsor
Amgen
Industry
Eligibility
50 Years and older
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
5
States / cities
Tempe, Arizona • Los Angeles, California • Denver, Colorado + 2 more
Source: ClinicalTrials.gov public record
Updated Jul 21, 2022 · Synced Sep 7, 2026, 11:08 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Surgeon-Initiated Bone Health Referral Pathway in Patients Undergoing Lower Extremity Arthroplasty

NCT05845021
View directory record Official record
Conditions
Osteoporosis, Arthroplasty Complications, Fragility Fracture
Interventions
Surgeon-Initiated Bone Health Referral Pathway
Combination Product
Lead sponsor
Johns Hopkins University
Other
Eligibility
50 Years and older
Enrollment
2,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2028
U.S. locations
1
States / cities
Columbia, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 13, 2025 · Synced Sep 7, 2026, 11:08 PM EDT
Completed Phase 2 Interventional

Parathyroid Hormone (PTH) With Alendronate for Osteoporosis

NCT00005006
View directory record Official record
Conditions
Osteoporosis
Interventions
Parathyroid Hormone, Alendronate, Teriparatide
Drug
Lead sponsor
Helen Hayes Hospital
Other
Eligibility
50 Years and older · Female only
Enrollment
140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1987 – 2006
U.S. locations
1
States / cities
West Haverstraw, New York
Source: ClinicalTrials.gov public record
Updated Aug 18, 2015 · Synced Sep 7, 2026, 11:08 PM EDT
Not listed No phase listed Observational Accepts healthy volunteers

Role of Cardiometabolic Risk Factors in Childhood Bone Development

NCT02355717
View directory record Official record
Conditions
Obesity, Cardiovascular Disease, Type 2 Diabetes, Osteoporosis
Interventions
Observational Study
Other
Lead sponsor
Augusta University
Other
Eligibility
9 Years to 15 Years
Enrollment
400 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2021
U.S. locations
1
States / cities
Augusta, Georgia
Source: ClinicalTrials.gov public record
Updated Nov 19, 2019 · Synced Sep 7, 2026, 11:08 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study Of SB-751689, Atorvastatin, Ketoconazole, And Rosuvastatin In Health Postmenopausal Women.

NCT00388596
View directory record Official record
Conditions
Osteoporosis
Interventions
SB-751689
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
Up to 65 Years · Female only
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2006
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Oct 12, 2008 · Synced Sep 7, 2026, 11:08 PM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Evaluation of the Spry Belt for Improving Bone Quality

NCT03986203
View directory record Official record
Conditions
Osteopenia
Interventions
Spry Belt
Device
Lead sponsor
Theranova, L.L.C.
Industry
Eligibility
50 Years and older · Female only
Enrollment
140 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2022
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Apr 5, 2022 · Synced Sep 7, 2026, 11:08 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Skeletal Response to Simulated Night Shift

NCT05074277
View directory record Official record
Conditions
Osteoporosis, Circadian Rhythm Sleep Disorder, Shift Work Type
Interventions
Simulated short term night shift work schedule
Behavioral
Lead sponsor
University of Colorado, Denver
Other
Eligibility
20 Years to 40 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2025
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Dec 21, 2025 · Synced Sep 7, 2026, 11:08 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Effect of Assessing Risk for Osteoporosis on Physician and Patient Behaviors

NCT01572766
View directory record Official record
Conditions
Osteoporosis, Osteopenia
Interventions
FRAX Assessment Tool
Other
Lead sponsor
Duquesne University
Other
Eligibility
45 Years to 65 Years · Female only
Enrollment
90 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 5, 2012 · Synced Sep 7, 2026, 11:08 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Lead Exposure, Genetics, and Osteoporosis Epidemiology

NCT00013637
View directory record Official record
Conditions
Osteoporosis
Interventions
Not listed
Lead sponsor
National Institute of Environmental Health Sciences (NIEHS)
NIH
Eligibility
0 Years and older · Female only
Enrollment
650 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
1998 – 2003
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 3, 2006 · Synced Sep 7, 2026, 11:08 PM EDT
Terminated Phase 3 Interventional Accepts healthy volunteers Results available

Averting Complications of Proton Pump Inhibitor Therapy by Effervescent Calcium Magnesium Citrate

NCT03812380
View directory record Official record
Conditions
Osteoporosis, Hypomagnesemia
Interventions
EffCaMgCit, Placebo
Drug · Other
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
21 Years to 99 Years
Enrollment
62 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2021
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Aug 16, 2022 · Synced Sep 7, 2026, 11:08 PM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers

Fructooligosaccharide and Calcium Absorption in Adolescent Girls

NCT01005927
View directory record Official record
Conditions
Osteoporosis
Interventions
Fructooligosaccharide
Dietary Supplement
Lead sponsor
Purdue University
Other
Eligibility
10 Years to 12 Years · Female only
Enrollment
26 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
1
States / cities
West Lafayette, Indiana
Source: ClinicalTrials.gov public record
Updated May 6, 2018 · Synced Sep 7, 2026, 11:08 PM EDT
Active, not recruiting Phase 4 Interventional

Muscle Impact of Treating Osteoporosis

NCT05666310
View directory record Official record
Conditions
Sarcopenia, Osteoporosis
Interventions
Denosumab, Zoledronic Acid, Denosumab Placebo, Zoledronic Acid Placebo
Drug · Other
Lead sponsor
Nami Safai Haeri
Other
Eligibility
65 Years and older · Female only
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 11, 2026 · Synced Sep 7, 2026, 11:08 PM EDT
Completed Phase 3 Interventional Results available

Twenty-Four Month Extension Study of BA058-05-003 (Abaloparatide) in Participants With Osteoporosis

NCT01657162
View directory record Official record
Conditions
Postmenopausal Osteoporosis
Interventions
Alendronate
Drug
Lead sponsor
Radius Health, Inc.
Industry
Eligibility
50 Years to 85 Years · Female only
Enrollment
1,139 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
3
States / cities
Lakewood, Colorado • Hialeah, Florida • Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 10, 2020 · Synced Sep 7, 2026, 11:08 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study of Blosozumab (LY2541546) in Postmenopausal Female Participants

NCT02109042
View directory record Official record
Conditions
Osteoporosis, Postmenopausal
Interventions
Blosozumab
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
60 Years and older · Female only
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
2
States / cities
Daytona Beach, Florida • Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jul 15, 2018 · Synced Sep 7, 2026, 11:08 PM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers Results available

One Week Parathyroid Hormone-related Protein (PTHrP) IV Dose Escalation Study

NCT00580788
View directory record Official record
Conditions
Osteoporosis, Humoral Hypercalcemia of Malignancy, Hyperparathyroidism
Interventions
PTHrP (1-36)
Drug
Lead sponsor
University of Pittsburgh
Other
Eligibility
24 Years to 35 Years
Enrollment
14 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2009
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 10, 2016 · Synced Sep 7, 2026, 11:08 PM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers Results available

7 Day Continuous Parathyroid Hormone IV Infusion

NCT00377312
View directory record Official record
Conditions
Osteoporosis, Bone Diseases, Endocrine, Hyperparathyroidism
Interventions
Parathyroid Hormone (1-34)
Drug
Lead sponsor
University of Pittsburgh
Other
Eligibility
24 Years to 35 Years
Enrollment
11 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2007
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 21, 2016 · Synced Sep 7, 2026, 11:08 PM EDT
Completed Phase 4 Interventional Results available

Effects of Zoledronic Acid and Raloxifene on Bone Turnover Markers in Postmenopausal Women With Low Bone Mineral Density

NCT00431444
View directory record Official record
Conditions
Osteoporosis
Interventions
Raloxifene, Zoledronic acid, Placebo oral pills, Placebo intravenous (i.v.) infusion
Drug
Lead sponsor
Novartis
Industry
Eligibility
45 Years to 80 Years · Female only
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
17
States / cities
Phoenix, Arizona • Buena Park, California • Washington D.C., District of Columbia + 12 more
Source: ClinicalTrials.gov public record
Updated Mar 28, 2011 · Synced Sep 7, 2026, 11:08 PM EDT
Completed No phase listed Observational

Genomic Determinants and Shared Genetic Pathways of Periodontal Disease

NCT03437798
View directory record Official record
Conditions
Periodontal Diseases, Diabetes, Osteoporosis, Cardiovascular Risk Factor
Interventions
Disease status
Other
Lead sponsor
Tufts University
Other
Eligibility
45 Years to 100 Years · Female only
Enrollment
81 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 10, 2024 · Synced Sep 7, 2026, 11:08 PM EDT
Completed Phase 3 Interventional Results available

Study of the Experience of Patients With Osteoporosis Using the Forteo B Pen to Self Administer Once Daily Teriparatide Therapy

NCT00577863
View directory record Official record
Conditions
Osteoporosis
Interventions
teriparatide
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
Not listed
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
18
States / cities
Huntsville, Alabama • Montgomery, Alabama • Peoria, Arizona + 15 more
Source: ClinicalTrials.gov public record
Updated Jul 21, 2009 · Synced Sep 7, 2026, 11:08 PM EDT
Completed Phase 3 Interventional

Comparison of Raloxifene Hydrochloride and Placebo in the Treatment of Postmenopausal Women With Osteoporosis

NCT00670319
View directory record Official record
Conditions
Osteoporosis, Postmenopausal
Interventions
Raloxifene HCL, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
Up to 80 Years · Female only
Enrollment
7,705 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1994 – 1999
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Apr 30, 2008 · Synced Sep 7, 2026, 11:08 PM EDT
Completed Phase 3 Interventional Results available

A Study to Test if TVB-009P is Effective in Relieving Postmenopausal Osteoporosis

NCT04729621
View directory record Official record
Conditions
Osteoporosis, Postmenopausal
Interventions
TVB-009, Prolia®
Combination Product
Lead sponsor
Teva Pharmaceuticals USA
Industry
Eligibility
60 Years to 90 Years · Female only
Enrollment
332 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
20
States / cities
Phoenix, Arizona • Tucson, Arizona • San Diego, California + 17 more
Source: ClinicalTrials.gov public record
Updated Apr 17, 2024 · Synced Sep 7, 2026, 11:08 PM EDT
Completed Phase 4 Interventional

Long Term Effects of Raloxifene Treatment on Bone Quality

NCT00532428
View directory record Official record
Conditions
Osteoporosis, Post-Menopausal
Interventions
Raloxifene, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
55 Years to 85 Years · Female only
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003
U.S. locations
2
States / cities
Indianapolis, Indiana • Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Sep 19, 2007 · Synced Sep 7, 2026, 11:08 PM EDT
Completed Phase 2 Interventional Results available

Transdermal Estrogen in Older Premenopausal Women With Anorexia Nervosa

NCT02475265
View directory record Official record
Conditions
Anorexia Nervosa, Osteoporosis
Interventions
estradiol 0.045 mg/levonorgestrel 0.015mg
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
25 Years to 50 Years · Female only
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 21, 2019 · Synced Sep 7, 2026, 11:08 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

The Relationship Between Vitamin D, Fingernail Thickness and Bone Density

NCT00006196
View directory record Official record
Conditions
Osteoporosis
Interventions
Vitamin D
Drug
Lead sponsor
National Center for Research Resources (NCRR)
NIH
Eligibility
25 Years to 75 Years · Female only
Healthy volunteers
Accepts healthy volunteers
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jun 23, 2005 · Synced Sep 7, 2026, 11:08 PM EDT